기업분석리포트 신규상장기업분석보고서 사업모델 평가보고서 및 기업 계속성 보고서 기업집단The BPPL 2024 saw the removing of five pathogen-antibiotic combos which were included in BPPL 2017, along with the addition of four new combos. The point that 3rd-generation cephalosporin-resistant EnterobacteralesThere ma